At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 295 enrolled
Drug / intervention
Camostat Mesilate +1 moredrug
Likely dose
Camostat Mesilate 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Camostat Mesilate for Treatment of COVID-19 in Outpatients
In Brief
A Phase 2 clinical trial evaluating Camostat Mesilate and Placebo for COVID-19. Completed, enrolled 295 participants across 21 sites.
Detailed Summary
This is a randomized, double-blind, placebo-controlled study of camostat mesilate in ambulatory patients with confirmed COVID-19 with at least one risk factor for severe illness.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionMar 2021
TodayJul 2026
First PostedOct 12, 2020
Enrollment StartNov 9, 2020
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.7 years ago
Interventions
Camostat Mesilatedrug
Camostat mesilate administered as oral 100 mg round tablets. Study dose: Two 100 mg tablets (200 mg total) taken orally 4 times daily for 14 days.
Placebodrug
Placebo administered as oral round tablets. Study dose: Two placebo tablets taken orally 4 times daily for 14 days.